Notably, ibrutinib and lenalidomide have been known to be active for CNS DLBCL [27,28], and both drugs have recently shown the feasibility in combination with R-CHOP [29,30]. Here, DDIT3 is linked to diffuse large B-cell lymphoma of the central nervous system.